Results 1 to 10 of about 12,722 (192)

Efficacy and safety of sacubitril/valsartan in end-stage renal disease patients with heart failure: a review [PDF]

Annals of Medicine
Purpose End-stage renal disease (ESRD) is associated with a heavy global public health burden and an increased risk of cardiovascular diseases. Sacubitril/valsartan has been shown to improve cardiovascular outcomes in patients with heart failure and ...
Peiyun Li, Yupei Li, Ling Zhang
doaj   +2 more sources

Efficacy and safety of sacubitril/valsartan combined with dapagliflozin in non-diabetic patients with advanced chronic kidney disease [PDF]

Frontiers in Endocrinology
BackgroundData on the effects of sacubitril/valsartan combined with dapagliflozin in non-diabetic patients with advanced chronic kidney disease (CKD) are limited.
Huifang Wang, Xianyi Li, Chunhui Jiang, Xuemei Liu   +3 more
doaj   +2 more sources

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial [PDF]

European Journal of Heart Failure, 2016
AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril ...
Orly Vardeny, Brian Lee Claggett, Milton Packer   +2 more
exaly   +3 more sources

Sacubitril-Valsartan

Reactions Weekly
Patel P, Nicolas D, Reed M.
europepmc   +9 more sources

Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure [PDF]

Revista Portuguesa de Cardiologia, 2019
The current paradigm of medical therapy for heart failure with reduced ejection fraction (HFrEF) is triple neurohormonal blockade with an angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB) and a mineralocorticoid receptor antagonist (MRA)
J. Silva-Cardoso, D. Brás, F. Canário-Almeida, A. Andrade, L. Oliveira, F. Pádua, C. Fonseca, N. Bragança, S. Carvalho, R. Soares, J. Ferreira Santos   +10 more
doaj   +3 more sources

Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study [PDF]

Frontiers in Cardiovascular Medicine, 2021
Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs ...
Swathi Pathadka, Vincent K. C. Yan, Xue Li, Xue Li, Xue Li, Gary Tse, Eric Y. F. Wan, Eric Y. F. Wan, Hayden Lau, Hayden Lau, Wallis C. Y. Lau, Wallis C. Y. Lau, David C. W. Siu, Esther W. Chan, Ian C. K. Wong, Ian C. K. Wong   +15 more
doaj   +3 more sources

Prescription Patterns of Sacubitril/Valsartan in an Outpatient Population Diagnosed with Heart Failure with Reduced Ejection Fraction After a Recent Hospitalization [PDF]

Epidemiologia
Background: Sacubitril/Valsartan is a first-line treatment for heart failure with reduced ejection fraction (HFrEF) according to international guidelines.
Dimitri Roustan, Hugo Bothorel, Omar Kherad   +2 more
doaj   +2 more sources

Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial [PDF]

Nature Communications
Diffuse interstitial fibrosis is associated with adverse outcomes in hypertensive heart disease and may be reversible. Sacubitril/valsartan could offer greater anti-fibrotic effects than valsartan alone.
Vivian Lee, Mayank Dalakoti, Qishi Zheng, Desiree-Faye Toh, Redha Boubertakh, Jennifer A. Bryant, Tar-Choon Aw, Chi-Hang Lee, A. Mark Richards, Javed Butler, Javier Díez, Roger Foo, Stuart A. Cook, Carolyn SP Lam, Thu-Thao Le, Calvin WL Chin   +15 more
doaj   +2 more sources

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction

Frontiers in Cardiovascular Medicine, 2021
Objectives: Although the PARAGON-HF trial failed to reach its primary endpoint, subgroups of patients with heart failure with preserved ejection fraction (HFpEF) still appear to benefit from Sacubitril/Valsartan therapy.
Christof Burgdorf, Janine Brockmöller, Henrieke Strampe, Monika Januszewski, Bjoern Andrew Remppis   +4 more
doaj   +1 more source

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis

Frontiers in Pharmacology, 2023
Background: The episode of acute decompensated heart failure (ADHF) is the main cause of hospitalization for heart failure (HF). Sacubitril–valsartan has been proven to be effective in reducing the risks of hospitalization for HF in ADHF.
Tianyang Hu, Yiting Liu, Yake Lou
doaj   +1 more source